ASCO 2024: Treatment-free survival with cabozantinib plus nivolumab
At the American Society of Clinical Oncology Annual Meeting (ASCO) last [...]
Real world data on the use of cabozantinib plus immunotherapy in the second line
A recent study looked at the use of a combination [...]
NICE approves cabozantinib plus nivolumab for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) has approved the [...]
METEOR study: Cabozantinib compared to everolimus in advanced kidney cancer
Cabozantinib is a tyrosine kinase inhibitor that is used [...]
ESMO 2023: Belzutifan for the treatment of advanced kidney cancer
Treatments for people with metastatic kidney cancer have changed over [...]
Nivolumab plus cabozantinib for advanced non-clear cell kidney cancer
Updated results and further follow up from the CaboNivo study [...]
Promising new anti-cancer treatment for advanced kidney cancer
The results of a study with a new anti-cancer medication [...]
Atezolizumab plus cabozantinib for previously treated metastatic kidney cancer
The results of the CONTACT-03 study with atezolizumab plus cabozantinib [...]
Triple combination for previously untreated advanced non-clear cell kidney cancer
The COSMIC-313 study previously showed improved survival when combining cabozantinib [...]
Cabozantinib plus atezolizumab in non-clear cell kidney cancer
The results from an extended follow-up of the phase 1b [...]
